Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DateTimeSourceHeadlineSymbolCompany
09/25/202412:00AMGlobeNewswire Inc.New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin TypesNASDAQ:ARQTArcutis Biotherapeutics Inc
09/24/20247:00AMGlobeNewswire Inc.FDA Accepts Arcutis’ Supplemental New Drug Application for ZORYVE® (roflumilast) Foam for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and OverNASDAQ:ARQTArcutis Biotherapeutics Inc
09/19/20247:00AMGlobeNewswire Inc.Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association DermatologyNASDAQ:ARQTArcutis Biotherapeutics Inc
09/05/20244:56PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
09/05/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
09/05/20247:00AMGlobeNewswire Inc.Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255NASDAQ:ARQTArcutis Biotherapeutics Inc
09/03/202412:37PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/28/20247:00AMGlobeNewswire Inc.Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
08/22/20247:00AMGlobeNewswire Inc.Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
08/15/20245:08AMIH Market NewsCisco Beats Estimates and Announces Restructuring, Canoo Rises 6%, Lulus Losses Widen, Latest in EarningsNASDAQ:ARQTArcutis Biotherapeutics Inc
08/14/20248:00PMGlobeNewswire Inc.CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
08/14/20243:12PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARQTArcutis Biotherapeutics Inc
08/14/20243:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
08/14/20243:00PMGlobeNewswire Inc.Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
08/14/20244:58AMIH Market NewsU.S. Futures Steady After Tuesday’s Strong Recovery; CPI in FocusNASDAQ:ARQTArcutis Biotherapeutics Inc
08/05/20243:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/05/20243:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/05/20243:37PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/02/20243:22PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/02/20243:19PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/02/20243:00PMGlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
08/01/20243:45PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
08/01/20243:00PMGlobeNewswire Inc.Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
07/29/20246:35AMGlobeNewswire Inc.Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.NASDAQ:ARQTArcutis Biotherapeutics Inc
07/29/20246:30AMGlobeNewswire Inc.Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
07/24/20243:10PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
07/23/20247:00AMGlobeNewswire Inc.Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and OverNASDAQ:ARQTArcutis Biotherapeutics Inc
07/22/20247:00AMGlobeNewswire Inc.Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOLNASDAQ:ARQTArcutis Biotherapeutics Inc
07/09/20243:53PMGlobeNewswire Inc.FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of AgeNASDAQ:ARQTArcutis Biotherapeutics Inc
07/09/20247:00AMGlobeNewswire Inc.Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Your Recent History

Delayed Upgrade Clock